Forte Biosciences, Inc.
Forte Biosciences, Inc. (FBRX): 4 pipeline candidates · ~10 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.6 months
D/E 0.60 · 0% dilution
Lead: Phase 2
4 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Forte Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$355.9M
Cash
$58.2M
Quarterly Burn
$18.8M
Runway
9.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| fb-102 | Phase 2 |
| fb102 | Phase 2 |
| fb102 multiple doses | Phase 2 |
| fb102 single dose | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
68
Total value held
$393.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,376,120 | $61.6M |
| federated hermes, inc. | 1,765,516 | $45.7M |
| fred alger management, llc | 1,273,965 | $33.0M |
| orbimed advisors llc | 1,196,955 | $31.0M |
| vanguard capital management llc | 1,063,384 | $27.5M |
| affinity asset advisors, llc | 1,011,890 | $26.2M |
| mpm bioimpact llc | 1,000,682 | $25.9M |
| adage capital partners gp, l.l.c. | 950,000 | $24.6M |
| woodline partners lp | 663,974 | $17.2M |
| morgan stanley | 500,298 | $13.0M |
Showing top 10 of 68 institutional holders of Forte Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Forte Biosciences, Inc.'s pipeline?
Forte Biosciences, Inc. (FBRX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Forte Biosciences, Inc.'s lead drug candidate?
Forte Biosciences, Inc.'s most advanced tracked candidate is fb-102 (Phase 2) for Alopecia Areata; Vitiligo; Celiac Disease.
What is Forte Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Forte Biosciences, Inc. has approximately 9.6 months of cash runway.
What is Forte Biosciences, Inc.'s market capitalization?
Forte Biosciences, Inc.'s market capitalization is approximately $355.9M.
Who is the CEO of Forte Biosciences, Inc.?
Dr. Paul A. Wagner Ph.D. is the chief executive officer of Forte Biosciences, Inc. (FBRX).
Get the full picture on Forte Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.